secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001790340-24-000069
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports 40% ORR, 80% DCR from IMM-1-104 combo in pancreatic cancer
------------------------------------------------------------------------------

- First patient had complete response; second unconfirmed partial; third/fourth stable disease; fifth equivocal progressive disease.
- 80% disease control rate and 40% overall response rate (RECIST) in first five patients; all remain on treatment.
- DSMB approved enrollment of additional patients at 320 mg QD; dosing has begun.
- Initial data from another Phase 2a arm of IMM-1-104 and Phase 1 data for IMM-6-415 expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000069/0001790340-24-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000069/imrx-20240912.htm
  HTML page:      https://secwatch.observer/filing/0001790340-24-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer